Bicocca Open Archive

Logo unimib boa
FAGIUOLI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.964
AS - Asia 14.714
EU - Europa 10.664
SA - Sud America 2.279
AF - Africa 228
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 15
Totale 42.884
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.580
SG - Singapore 4.888
HK - Hong Kong 3.657
RU - Federazione Russa 2.983
VN - Vietnam 2.802
CN - Cina 2.172
BR - Brasile 1.846
IT - Italia 1.830
IE - Irlanda 1.761
DE - Germania 1.381
SE - Svezia 1.241
IN - India 357
GB - Regno Unito 352
CA - Canada 272
UA - Ucraina 233
AR - Argentina 177
ID - Indonesia 160
KR - Corea 135
FI - Finlandia 134
NL - Olanda 126
AT - Austria 119
FR - Francia 116
BD - Bangladesh 100
ZA - Sudafrica 93
PL - Polonia 79
MX - Messico 78
EC - Ecuador 71
ES - Italia 71
TR - Turchia 66
IQ - Iraq 65
JP - Giappone 62
DK - Danimarca 53
CO - Colombia 49
BE - Belgio 39
VE - Venezuela 39
PK - Pakistan 31
PY - Paraguay 31
SA - Arabia Saudita 29
MY - Malesia 28
CL - Cile 27
EG - Egitto 27
CZ - Repubblica Ceca 26
MA - Marocco 25
KE - Kenya 21
UZ - Uzbekistan 20
TN - Tunisia 19
PT - Portogallo 17
PE - Perù 15
RO - Romania 15
TW - Taiwan 15
DZ - Algeria 14
IR - Iran 14
JO - Giordania 13
LT - Lituania 13
UY - Uruguay 13
AE - Emirati Arabi Uniti 12
CH - Svizzera 12
EU - Europa 12
AL - Albania 11
BO - Bolivia 10
AU - Australia 9
BG - Bulgaria 9
OM - Oman 9
DO - Repubblica Dominicana 8
JM - Giamaica 8
NO - Norvegia 8
NP - Nepal 8
PH - Filippine 8
AZ - Azerbaigian 7
IL - Israele 7
BH - Bahrain 6
ET - Etiopia 6
KG - Kirghizistan 6
PA - Panama 6
AO - Angola 5
GR - Grecia 5
KZ - Kazakistan 5
RS - Serbia 5
TH - Thailandia 5
XK - ???statistics.table.value.countryCode.XK??? 5
EE - Estonia 4
LB - Libano 4
LY - Libia 4
MM - Myanmar 4
NZ - Nuova Zelanda 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
BY - Bielorussia 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
GA - Gabon 3
HN - Honduras 3
HU - Ungheria 3
KW - Kuwait 3
LK - Sri Lanka 3
MD - Moldavia 3
PS - Palestinian Territory 3
QA - Qatar 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
Totale 42.857
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.646
Singapore 2.838
Dublin 1.711
Ashburn 1.417
Ann Arbor 1.271
Frankfurt am Main 976
Ho Chi Minh City 910
Princeton 886
New York 828
Hanoi 744
Fairfield 672
Chandler 662
Santa Clara 606
Dallas 535
Woodbridge 464
Milan 459
Houston 453
Los Angeles 382
Moscow 360
Lawrence 327
Beijing 322
Altamura 321
Wilmington 316
Hefei 285
Seattle 252
Cambridge 249
Buffalo 221
Chicago 178
Shanghai 177
The Dalles 175
Jacksonville 167
São Paulo 166
San Diego 160
Pune 157
Dearborn 143
Rome 128
Jakarta 126
Seoul 121
Toronto 116
London 97
Andover 89
Haiphong 86
Da Nang 84
Salt Lake City 84
Nuremberg 78
Rio de Janeiro 72
Guangzhou 69
Quận Bình Thạnh 65
Munich 63
Nanjing 62
Vienna 62
Washington 58
Warsaw 57
Tokyo 55
Thái Nguyên 53
Brooklyn 51
Hải Dương 51
Ha Long 49
Hangzhou 49
Biên Hòa 46
Helsinki 46
Johannesburg 44
Boston 43
Stockholm 40
Atlanta 39
Phoenix 39
Vũng Tàu 39
Boardman 38
Fremont 38
Montreal 38
Ninh Bình 38
Brasília 36
Chennai 36
Council Bluffs 35
Tampa 35
Columbus 34
Lappeenranta 34
Bergamo 32
Denver 32
Elk Grove Village 32
Belo Horizonte 31
Quận Phú Nhuận 30
Curitiba 29
Shenyang 29
Changsha 28
Lachine 28
Quito 28
San Francisco 28
Ottawa 27
Quận Một 27
Tianjin 27
Brussels 26
Bắc Ninh 25
Can Tho 25
Mexico City 25
Orem 25
Guayaquil 24
Porto Alegre 24
Dhaka 23
Manchester 23
Totale 26.587
Salva come PNG Salva come JPEG
Nome #
Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma 1.229
Vaccinations in Paediatric Solid Organ Transplant Candidates and Recipients 432
Estimation of lifetime costs for patients receiving a transplant: the case of liver transplantation related to hepatitis B in Italy 425
Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group 424
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology 393
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 333
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 296
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 276
Health related quality of life in chronic liver diseases 272
Value-based outcome indicators in the management of hepatocellular carcinoma: Clinical test in a large multicenter study (VBMH study) 271
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 266
Generation and performance of value-based outcome indicators in liver disease: The multicenter V.B.M.H. study 261
Outcome indicators in liver cirrhosis: Application of value-based medicine in a large multicenter study (VBMH study) 258
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 253
P1169 : Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 252
Outcome indicators in primary sclerosing cholangitis: Interim analysis of the value-based medicine in hepatology study 250
HCC persistence or recurrence after bridging therapy helps predict transplant list dropout and generate a more equitable exception policy 247
High rates of 30-day mortality in patients with cirrhosis and COVID-19 243
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 243
Outcome Indicators in Primary Sclerosing Cholangitis: Interim Analysis Of The Value-Based Medicine In Hepatology (VBMH) Study 242
Value-based outcome indicators in liver cirrhosis: validation in a large multicenter study (VBMH study) 240
The impact of liver disease on the health-related quality of life 235
Measurement of clinical outcomes and quality of life indicators as a new value-based approach to liver cirrhosis management 233
Generation and Performance of Outcome Indicators in Liver Cirrhosis: The Value Based Medicine in Hepatology Study (V.B.M.H.) 231
Health Related Quality of Life in the Major Liver Conditions 231
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis 229
The Impact of Type of Liver Conditions on the Patients’ Health Related Quality of Life 225
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 223
A Comparison Between The Health-Related Quality Of Life Reported By The General Population And By Patients With Major Liver Diseases 223
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 219
A value-based approach to the management of patients with liver cirrhosis through the systematic measurement of clinical outcome and quality of life indicators 216
Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine 215
COVID-19: role of resilience on the psychological impact of lockdown in liver transplant transitional candidates and recipients COVID-19: ruolo della resilienza sull’impatto psicologico del lockdown nei candidati e nei riceventi del trapianto di fegato (adolescenti-giovani adulti) 210
Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases 210
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching 208
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 208
Value-based approach to hepatocellular carcinoma: outcome indicators tested in a large multicenter study (VBMH study) 200
Balancing donor and recipient risk factors in liver transplantation: The value of D-MELD with particular reference to HCV recipients 200
Treatment of hepatocellular carcinoma: A cost analysis of yttrium-90 transarterial radioembolization versus sorafenib 200
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 195
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list 195
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS) 195
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 194
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 190
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 190
Vaccination Recommendations in Solid Organ Transplant Adult Candidates and Recipients 186
Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria 186
Combined double lung-liver transplantation for cystic fibrosis without cardio-pulmonary by-pass. 185
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 184
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 184
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients 177
Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite. 176
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 176
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055)) 176
The Italian data on SARS-CoV-2 infection in transplanted patients support an organ specific immune response in liver recipients 174
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 170
Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting 168
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study 168
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 167
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 166
Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study 165
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 163
The SURF (Italian observational study for renal insufficiency evaluation in liver transplant recipients): A post-hoc between-sex analysis 162
COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study 161
A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study 160
Percutaneous management of chronic total occlusion of the portal vein: a retrospective analysis of technical aspects and outcomes 159
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection 159
Selective use of ex-situ machine perfusion after normothermic regional perfusion in liver transplantation from donation after circulatory death 159
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 158
Correction: Immunosuppression in adult liver transplant recipients: a 2024 update from the Italian Liver Transplant Working Group (Hepatology International, (2024), 18, 5, (1416-1430), 10.1007/s12072-024-10703-4) 157
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study 157
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 156
Bergamo and Covid-19: How the Dark Can Turn to Light 154
Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis 152
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 149
Antibiotic Stewardship Based on Colonization with Multi-Drug-Resistant Bacteria in Liver Transplantation: A Narrative Review 148
HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation 148
Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x) 147
Physiological reno-portal bypass in liver transplantation with non-tumorous portal vein thrombosis 146
The Role of Imaging in Portal Vein Thrombosis: From the Diagnosis to the Interventional Radiological Management 144
Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue 142
Current Endovascular Management of Arterial Complications After Pediatric Liver Transplantation in a Tertiary Center 142
Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients 140
Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19” 139
Extended criteria liver donation after circulatory death with prolonged warm ischemia: a pilot experience of normothermic regional perfusion and no subsequent ex-situ machine perfusion 138
Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study 137
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool 137
Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and meta-analysis 137
Safety and Efficacy of Subcutaneous Hepatitis B Immunoprophylaxis using “on demand” Approach: A Single Center Experience 136
Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness 136
Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation 134
Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study 134
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference 133
Citolisi e colestasi post-oltx per cirrosi HCV: l’enigma della diagnosi differenziale 133
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments 132
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation 131
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial 130
Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis 129
Preparing for future waves and pandemics: a global hospital survey on infection control measures and infection rates in COVID-19 127
Consensus conference on TIPS management: Techniques, indications, contraindications 124
Totale 20.619
Salva come PNG Salva come JPEG
Categoria #
all - tutte 210.328
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 210.328
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021881 0 0 0 0 0 123 134 162 120 118 79 145
2021/20223.656 81 115 168 213 68 155 43 1.395 86 314 245 773
2022/20235.072 798 1.485 460 295 306 871 64 292 218 61 150 72
2023/20245.053 74 128 152 226 754 1.452 973 162 461 73 64 534
2024/202514.328 822 1.742 601 606 1.226 389 614 462 2.010 1.826 966 3.064
2025/202611.929 2.866 1.925 1.987 2.256 2.707 188 0 0 0 0 0 0
Totale 44.532